Glucose abnormalities in infants with birth asphyxia are associated with later neurological diagnoses
: Viitaharju, Niina; Parikka, Vilhelmiina; Löyttyniemi, Eliisa; Singh, Bishwesvar; Helenius, Kjell
: 2026
Early Human Development
: 106536
: 218
: 0378-3782
: 1872-6232
DOI: https://doi.org/10.1016/j.earlhumdev.2026.106536
: https://doi.org/10.1016/j.earlhumdev.2026.106536
: https://research.utu.fi/converis/portal/detail/Publication/522873695
Objective
To investigate the association between early glycemic profile and neurological outcome in neonates with birth asphyxia.
Study designRetrospective single-center study on infants born ≥36 weeks gestational age with an ICD-10 diagnosis of birth asphyxia and/or hypoxic-ischemic encephalopathy, using early (<72 h) glucose values and clinical follow-up data extracted from medical records. Outcomes: death or any ICD-10 diagnoses indicating neurodevelopmental disorders (NDD; psychiatric, epileptical, paralytical, visual or hearing disorders) and individual diagnostic classes. Estimates were adjusted for infant sex, delivery mode and therapeutic hypothermia.
ResultsAmong 272 neonates, 44 infants received therapeutic hypothermia and 228 infants did not. In multivariate analyses of all infants, the association was significant between glucose <2.6 mmol/l and hearing disorders (aOR = 6.7, 95%CI 1.2–37.3). Glucose >8.3 mmol/l was significantly associated with cerebral palsy (OR = 4.5, 95%Cl 1.2–16.4) and hearing disorders (OR = 6.1, 95%Cl 1.2–29.7). In univariate analyses of the 228 infants who did not receive therapeutic hypothermia, both hypoglycemia and hyperglycemia were associated with cerebral palsy: glucose <2.6 mmol/l: OR 5.63 (1.1–29.7) and >8.3 mmol/l OR 8.83 (1.88–41.47); epilepsy: glucose <1.6 mmol/l: OR 12.2 (1.6–91.9) and >8.3 mmol/l 19.4 (2.0–192.6); and hearing disorders: glucose<1.6 mmol/l OR 8.1 (1.3–51.7) and >8.3 mmol/l OR 9.7 (1.6–60.2).
ConclusionsThis study suggests that the glycemic profile in neonates with birth asphyxia during the first 72 h is associated with neurodevelopmental disorders. Further research is needed to verify these findings and investigate if neurological outcome could be improved by rigorous glycemic control.
:
This research was supported by Foundation of Turku University Central Hospital, Foundation for Pediatric Research, Finland (Grant numbers 240099, 240413, 210225 and 240032), The South-Western Finnish Foundation of Neonatal Research and State research grant (Hospital district of Southwest Finland, 13255 and 30013). The funding sources had no role in the study design, collection, analysis and interpretation of data, writing of the report and decision to submit the article for publication.